T-DXd Tolerability in Community-Treated HER2-Low Metastatic Breast Cancer: What Real-World Practice Is Showing

from TheBrief.Health · host TheBrief.Health

Trastuzumab Deruxtecan is becoming standard for HER2-low metastatic breast cancer, with safe community use requiring careful monitoring, patient education, and early management of serious lung-related side effects.

Episode metadata supplied by the publisher feed · Published Apr 21, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

T-DXd Tolerability in Community-Treated HER2-Low Metastatic Breast Cancer: What Real-World Practice Is Showing

0:00 1:48

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of TheBrief.Health?

This episode is 1 minute long.

When was this TheBrief.Health episode published?

This episode was published on April 21, 2026.

Can I download this TheBrief.Health episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!